Dr. John Cush RheumNow
7 years 6 months ago
117 pregnancies exposed to biologics were compared to 585 pregnancies not exposed to biologics; 6% of newborns had ≥1 congenital anomalies. No significant association between biologic exposure and congenital anomalies (HR 1.06; 95%CI 0.46-2.47) was seen. https://t.co/bLOtPTmpL1
RheumNow Live Preview with Dr. Arthur Kavanaugh
Preview of Dr. Arthur Kavanaugh's lecture on New Data & Evolving Trends in Psoriatic Arthritis Therapy at the 2019 RheumNow Live meeting.
Dr. John Cush RheumNow
7 years 6 months ago
36 studies of 6662 depression patients shows the addition of antiinflammatory drugs (NSAIDs, steriods, statins, cytokine inhib, minocycline) improved antidepressant effects in Major Depression pts without increasing the risk of side‐effects. https://t.co/RdRNtVCfjh
Dr. John Cush RheumNow
7 years 6 months ago
MMWR reports that for the 8th yr in a row the US TB rate dropped 1.3% to 2.8 per 100,000. In 2018 there were 9029 TB cases (69% in non–U.S.-born). TB risk in non-US born was >14 times that of U.S.-born persons. https://t.co/qdzvyavNVX
Dr. John Cush RheumNow
7 years 6 months ago
Claims data shows among 60 028 psoriasis or psoriatic arthritis pts, there was NO significant difference in the risk of developing atrial fibrillation or major adverse cardiovascular events with ustekinumab (vs a TNF inhibitor) https://t.co/kJhUsmupLx
A study from UT Southwestern and the Baylor Research Institute examined the preceptions and practices of women with autoimmune or inflammatory rheumatic diseases (AIRD) noting that an AIRD diagnosis changed most womens future hopes and plans regarding pregnancy and lactation.
The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of osteoporotic fracture, including those with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.
Dr. John Cush RheumNow
7 years 6 months ago
ACR announces the agenda and faculty for the 2019 Annual ACR meeting (Atlanta) - Premeeting begins Octobr 19th and Scientific program begins Sunday Oct. 21, 2019. https://t.co/pNwEpgmCTX
Dr. John Cush RheumNow
7 years 6 months ago
A downward trend in Rheumatology fellowship positions reversed after 2013 and since (2014-17) there has been a 44% increase in fellowship positions (230-332), more than other subspecialties. More applicants per position, more US grads, higher salaries. https://t.co/STbmG4QnSA
RheumNow Live Preview with Dr. Len Calabrese
Preview of Dr. Len Calabrese's lecture on Immune Related Adverse Events with Checkpoint Inhibitors at the 2019 RheumNow Live meeting.
Dr. John Cush RheumNow
7 years 6 months ago
Long term tofacitinib in RA shows lymphocyte #s dropped ~24% by 48 mos. Monitor ALC at baseline & q3 mos; ALC <500 seen in 1.2% of 2983 pts and was assoc w/ higher risk of SIE & Zoster. ALC <500 more likely with low ALC, age, higher dose Tofa & MTX https://t.co/5CHMmoGWJw
A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.
A retrospective population-based cohort study of incident gout between 2006-2009 identified those with CKD; defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date.
Dr. John Cush RheumNow
7 years 6 months ago
US Veterans Study examined 17,415 patients starting MTX - only 20.6% started a biologic w/in 2-yrs. Biologic use was significantly lower in elderly [aHR 0.20 ≥ 80 vs < 50], pts w/ comorbidities [aHR 0.79], CHF [0.68], cancer [0.78] & nonwhites [0.79] https://t.co/3LcPVQAgcp
“If you don't know what you want, you end up with a lot you don't.” ― Chuck Palahniuk, "Fight Club" 1999
I have been a clinical investigator for 16 years, engaged in phase I to IV company-sponsored trials as well as NIH and investigator initiated studies. There are certain rules - written and unwritten - for participating in research as an investigator.
Dr. John Cush RheumNow
7 years 6 months ago
151 pts w/ myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) were treated with either rituximab or PBO showing no effect of RTX!! Really? someone, somewhere believes ME/CFS or FM is an immunologic dz? Do NOT use biologics, DMARDS in such pts. https://t.co/1xXG94QEnP

